Literature DB >> 6276153

Evidence for an active step in thyroid hormone transport to nuclei: drug inhibition of L-125I-triiodothyronine binding to nuclear receptors in rat pituitary tumor cells.

J Halpern, P M Hinkle.   

Abstract

When added to intact GH4Cl or GH3 cells, cytochalasin b, dansylcadaverine, and chloroquine inhibited the binding of L-125I-triiodothyronine (T3) to nuclear receptors within 30 min. These drugs also reduced the amount of 125I-T3 in the post-nuclear supernatant fraction of cells lysed with Triton X-100. If 125I-T3 was added before the drugs, 125I-T3 that was already bound did not dissociate, but further binding was blocked. Inhibition due to 10 microM cytochalasin b or 150 microM dansylcadaverine was reversible within 2 h of drug removal, and inhibition due to 150 microM chloroquine was partially reversible. Drug inhibition was overcome as the T3 concentration was raised. These drugs did not significantly inhibit 125I-T3 binding to isolated nuclei, and nuclei isolated from drug-treated cultures bound as much 125I-T3 as control nuclei. The results suggest that thyroid hormones reach their nuclear binding sites by an active transport process which is inhibited by the drugs studied.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6276153     DOI: 10.1210/endo-110-3-1070

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  3 in total

1.  Role of sodium in thyroid hormone uptake by rat skeletal muscle.

Authors:  M Centanni; J Robbins
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

2.  Internalization of triiodothyronine-bovine serum albumin-colloidal gold complexes in human peripheral leukocytes.

Authors:  Z Kostrouch; I Raska; V Felt; J Nedvídková; E Holecková
Journal:  Experientia       Date:  1987-10-15

3.  Plasma membrane transport of thyroid hormone: its possible pathophysiological significance.

Authors:  E P Krenning; R Docter; T J Visser; G Hennemann
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.